Preclinical Data on Humanized CD19 CAR-T Cells for B Cell Malignancies

A 1.5 MB PDF authored by Clara de Oliveira Andrade details the development and evaluation of two novel humanized anti-CD19 CAR-T cell constructs. The document, last updated in May 2026, reports results from in vitro cytotoxicity assays and in vivo xenograft models of B-cell acute lymphoblastic leukemia. It compares the performance of humanized variants H1 and H2 against the murine-derived FMC63 benchmark.

Use Cases

• Benchmarking novel CAR-T cell constructs based on reported binding affinity and functional performance data.
• Studying the impact of antibody humanization on T-cell persistence and exhaustion markers based on in vivo model results.
• Evaluating scalable, non-viral manufacturing strategies for CAR-T therapies as described in the conclusions.

Strengths

• Document is licensed under CC-BY-4.0, permitting broad reuse with attribution.
• Description provides specific details on experimental constructs (H1, H2), methods (Sleeping Beauty transposon), and comparative results.

Limitations

• Column-level documentation is absent; field semantics must be inferred after download.
• Row count is unknown, which may limit suitability assessment.
• The primary data underlying the reported results is not directly accessible; the file is a summary PDF.

Provenance

Source

figshare

Collection Method

Likely contains summarized experimental data from the described preclinical study.

Freshness

Last updated 2026-05-26 08:48:55; freshness should be verified.